CN104189553A - 含辅酶q10与植物油的组合物在制备预防骨质疏松的保健食品及药品的应用 - Google Patents
含辅酶q10与植物油的组合物在制备预防骨质疏松的保健食品及药品的应用 Download PDFInfo
- Publication number
- CN104189553A CN104189553A CN201410373489.7A CN201410373489A CN104189553A CN 104189553 A CN104189553 A CN 104189553A CN 201410373489 A CN201410373489 A CN 201410373489A CN 104189553 A CN104189553 A CN 104189553A
- Authority
- CN
- China
- Prior art keywords
- oil
- vegetable oil
- osteoporosis
- ubiquinone
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 63
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 63
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 38
- 239000008158 vegetable oil Substances 0.000 title claims abstract description 31
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims abstract description 30
- 235000013402 health food Nutrition 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims description 27
- 239000003814 drug Substances 0.000 title abstract description 8
- 230000003405 preventing effect Effects 0.000 title abstract description 6
- 229940110767 coenzyme Q10 Drugs 0.000 title abstract 7
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003921 oil Substances 0.000 claims abstract description 15
- 235000019198 oils Nutrition 0.000 claims abstract description 15
- 239000007901 soft capsule Substances 0.000 claims abstract description 8
- 235000004347 Perilla Nutrition 0.000 claims abstract description 4
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 4
- 235000019498 Walnut oil Nutrition 0.000 claims abstract description 4
- 239000008170 walnut oil Substances 0.000 claims abstract description 4
- 239000003549 soybean oil Substances 0.000 claims abstract description 3
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 3
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 56
- 229940035936 ubiquinone Drugs 0.000 claims description 56
- 230000002265 prevention Effects 0.000 claims description 19
- 210000000582 semen Anatomy 0.000 claims description 12
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 5
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 5
- 229960003720 enoxolone Drugs 0.000 claims description 5
- 229940089161 ginsenoside Drugs 0.000 claims description 5
- 229930182494 ginsenoside Natural products 0.000 claims description 5
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 abstract description 17
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 238000011160 research Methods 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 210000000963 osteoblast Anatomy 0.000 abstract description 3
- 239000010497 wheat germ oil Substances 0.000 abstract 2
- 235000019483 Peanut oil Nutrition 0.000 abstract 1
- 235000008524 evening primrose extract Nutrition 0.000 abstract 1
- 239000010475 evening primrose oil Substances 0.000 abstract 1
- 229940089020 evening primrose oil Drugs 0.000 abstract 1
- 235000001497 healthy food Nutrition 0.000 abstract 1
- 239000000312 peanut oil Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000008159 sesame oil Substances 0.000 abstract 1
- 235000011803 sesame oil Nutrition 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 29
- 241000700159 Rattus Species 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 230000001009 osteoporotic effect Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010065687 Bone loss Diseases 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000004097 bone metabolism Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 206010039984 Senile osteoporosis Diseases 0.000 description 2
- 229960004343 alendronic acid Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- -1 oxygen free radical Chemical class 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CGVPQHIRIGIDLE-UHFFFAOYSA-N 3-(2-aminooxyphenyl)propanoic acid Chemical compound NOC1=CC=CC=C1CCC(O)=O CGVPQHIRIGIDLE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 108010051842 Advanced Oxidation Protein Products Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 1
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000078511 Microtome Species 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000021864 drug-induced osteoporosis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 101150046266 foxo gene Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810180131.0A CN108283313A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与花生油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201810179598.3A CN108272835A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与月见草油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201810180504.4A CN108272968A (zh) | 2014-07-26 | 2014-07-26 | 含辅酶q10与小麦胚芽油的组合物在制备预防骨质疏松的保健食品及药品的应用 |
CN201810180109.6A CN108283654A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与芝麻油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201410373489.7A CN104189553A (zh) | 2014-07-26 | 2014-07-26 | 含辅酶q10与植物油的组合物在制备预防骨质疏松的保健食品及药品的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410373489.7A CN104189553A (zh) | 2014-07-26 | 2014-07-26 | 含辅酶q10与植物油的组合物在制备预防骨质疏松的保健食品及药品的应用 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810179598.3A Division CN108272835A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与月见草油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201810180131.0A Division CN108283313A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与花生油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201810180504.4A Division CN108272968A (zh) | 2014-07-26 | 2014-07-26 | 含辅酶q10与小麦胚芽油的组合物在制备预防骨质疏松的保健食品及药品的应用 |
CN201810180109.6A Division CN108283654A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与芝麻油制备预防骨质疏松的保健食品配方及生产工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104189553A true CN104189553A (zh) | 2014-12-10 |
Family
ID=52075024
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810179598.3A Withdrawn CN108272835A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与月见草油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201810180504.4A Withdrawn CN108272968A (zh) | 2014-07-26 | 2014-07-26 | 含辅酶q10与小麦胚芽油的组合物在制备预防骨质疏松的保健食品及药品的应用 |
CN201810180131.0A Withdrawn CN108283313A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与花生油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201810180109.6A Withdrawn CN108283654A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与芝麻油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201410373489.7A Pending CN104189553A (zh) | 2014-07-26 | 2014-07-26 | 含辅酶q10与植物油的组合物在制备预防骨质疏松的保健食品及药品的应用 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810179598.3A Withdrawn CN108272835A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与月见草油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201810180504.4A Withdrawn CN108272968A (zh) | 2014-07-26 | 2014-07-26 | 含辅酶q10与小麦胚芽油的组合物在制备预防骨质疏松的保健食品及药品的应用 |
CN201810180131.0A Withdrawn CN108283313A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与花生油制备预防骨质疏松的保健食品配方及生产工艺 |
CN201810180109.6A Withdrawn CN108283654A (zh) | 2014-07-26 | 2014-07-26 | 辅酶q10与芝麻油制备预防骨质疏松的保健食品配方及生产工艺 |
Country Status (1)
Country | Link |
---|---|
CN (5) | CN108272835A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840385A (zh) * | 2015-04-11 | 2015-08-19 | 广东医学院 | 一组润肤防皱抗衰老的辅酶q10护肤霜 |
CN104840375A (zh) * | 2015-04-11 | 2015-08-19 | 广东医学院 | 一组祛斑抗皱美白的辅酶q10面膜 |
CN104840376A (zh) * | 2015-04-15 | 2015-08-19 | 广东医学院 | 一组洁肤润肤养护皮肤的辅酶q10洁面乳 |
CN107625127A (zh) * | 2017-11-14 | 2018-01-26 | 广东环境保护工程职业学院 | 南极磷虾油和泛醌的协同抗疲劳组合物、胶囊及制备方法 |
CN110585266A (zh) * | 2019-09-18 | 2019-12-20 | 广东润和生物科技有限公司 | 紫苏籽油与辅酶q10组合物的应用 |
CN115779000A (zh) * | 2022-12-22 | 2023-03-14 | 广东润和生物科技有限公司 | 防治骨关节炎的辅酶q10组合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111700197A (zh) * | 2020-06-30 | 2020-09-25 | 海南大白康健医药股份有限公司 | 一种水溶性辅酶q10饮料及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1323588A (zh) * | 2000-05-16 | 2001-11-28 | 广东医学院医药科技开发中心 | 人参及人参茎叶提取物防治骨质疏松症的新用途 |
CN1446549A (zh) * | 2002-03-25 | 2003-10-08 | 广东医学院医药科技开发中心 | 甘草及甘草提取物防治骨质疏松症的新用途 |
CN1709424A (zh) * | 2005-06-08 | 2005-12-21 | 广东医学院 | 几种植物油在防治骨质疏松及皮肤衰老药物制剂中的应用 |
CN101283796A (zh) * | 2008-05-08 | 2008-10-15 | 昆明云大医药开发有限公司 | 以核桃油为基质的治疗骨质疏松及心脑血管病的保健品 |
-
2014
- 2014-07-26 CN CN201810179598.3A patent/CN108272835A/zh not_active Withdrawn
- 2014-07-26 CN CN201810180504.4A patent/CN108272968A/zh not_active Withdrawn
- 2014-07-26 CN CN201810180131.0A patent/CN108283313A/zh not_active Withdrawn
- 2014-07-26 CN CN201810180109.6A patent/CN108283654A/zh not_active Withdrawn
- 2014-07-26 CN CN201410373489.7A patent/CN104189553A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1323588A (zh) * | 2000-05-16 | 2001-11-28 | 广东医学院医药科技开发中心 | 人参及人参茎叶提取物防治骨质疏松症的新用途 |
CN1446549A (zh) * | 2002-03-25 | 2003-10-08 | 广东医学院医药科技开发中心 | 甘草及甘草提取物防治骨质疏松症的新用途 |
CN1709424A (zh) * | 2005-06-08 | 2005-12-21 | 广东医学院 | 几种植物油在防治骨质疏松及皮肤衰老药物制剂中的应用 |
CN101283796A (zh) * | 2008-05-08 | 2008-10-15 | 昆明云大医药开发有限公司 | 以核桃油为基质的治疗骨质疏松及心脑血管病的保健品 |
Non-Patent Citations (1)
Title |
---|
HO-JIN MOON等: "Coenzyme Q10 Regulates Osteoclast and Osteoblast Differentiation", 《JOURNAL OF FOOD SCIENCE》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104840385A (zh) * | 2015-04-11 | 2015-08-19 | 广东医学院 | 一组润肤防皱抗衰老的辅酶q10护肤霜 |
CN104840375A (zh) * | 2015-04-11 | 2015-08-19 | 广东医学院 | 一组祛斑抗皱美白的辅酶q10面膜 |
CN104840376A (zh) * | 2015-04-15 | 2015-08-19 | 广东医学院 | 一组洁肤润肤养护皮肤的辅酶q10洁面乳 |
CN107625127A (zh) * | 2017-11-14 | 2018-01-26 | 广东环境保护工程职业学院 | 南极磷虾油和泛醌的协同抗疲劳组合物、胶囊及制备方法 |
CN107625127B (zh) * | 2017-11-14 | 2020-09-29 | 广东环境保护工程职业学院 | 南极磷虾油和泛醌的协同抗疲劳组合物、胶囊及制备方法 |
CN110585266A (zh) * | 2019-09-18 | 2019-12-20 | 广东润和生物科技有限公司 | 紫苏籽油与辅酶q10组合物的应用 |
CN115779000A (zh) * | 2022-12-22 | 2023-03-14 | 广东润和生物科技有限公司 | 防治骨关节炎的辅酶q10组合物 |
CN115779000B (zh) * | 2022-12-22 | 2023-08-29 | 广东润和生物科技有限公司 | 防治骨关节炎的辅酶q10组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN108272968A (zh) | 2018-07-13 |
CN108283654A (zh) | 2018-07-17 |
CN108283313A (zh) | 2018-07-17 |
CN108272835A (zh) | 2018-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104189553A (zh) | 含辅酶q10与植物油的组合物在制备预防骨质疏松的保健食品及药品的应用 | |
Mobasheri et al. | Osteogenic effects of resveratrol in vitro: potential for the prevention and treatment of osteoporosis | |
ES2631988T3 (es) | Composición farmacéutica que comprende mioinositol y D-quiro-inositol | |
JP2007535575A (ja) | 生物活性化合物およびその使用方法 | |
CN104187627B (zh) | 一种降血脂组合物及其在制备具有降血脂功能的保健食品中的应用 | |
CN107771946A (zh) | 一种有助于中老年人心脑血管健康的配方奶粉及其生产方法 | |
KR101150643B1 (ko) | 선복화 추출물로부터 분리된 화합물을 유효성분으로 함유하는 염증 또는 알러지 질환의 예방 및 치료용 조성물 | |
CN102292093A (zh) | 用于代谢综合症控制的选自绒毛戴星草和莽吉柿的混合物 | |
CN105232525A (zh) | 一种降血脂药物组合物及其应用 | |
CN102302153B (zh) | 保健组合物及其制备方法和用途 | |
Liu et al. | Unsaturated fatty acids in natural edible resources, a systematic review of classification, resources, biosynthesis, biological activities and application | |
JP5846350B2 (ja) | 骨疾患予防又は治療用組成物 | |
JP2020189838A (ja) | コレステロール改善とトリアシルグリセロール代謝を促す薬物化合物生成における漢方薬配合の使用方法 | |
DE102017105036A1 (de) | Mittel zur Anwendung bei der Behandlung der Dyslipidämie | |
CN103735623A (zh) | 辅助降血脂片 | |
KR101318210B1 (ko) | 소회향 종자 추출물을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 조성물 | |
CN102429223A (zh) | 一种具有辅助降血脂功能的保健食品及其制备方法 | |
TWI542342B (zh) | 應用白藜蘆醇與薑黃素於脂肪肝治療之用途、醫藥組合物及其製備方法 | |
CN107837298A (zh) | 一种沙棘油保健品 | |
JP2007031302A (ja) | アディポネクチン産生促進剤、及び代謝異常症候群予防剤 | |
CN109364202B (zh) | 一种组合物及其制备方法和应用 | |
KR101457117B1 (ko) | 관중 추출물을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물 및 건강기능식품 | |
CN107693598A (zh) | 一种降血脂的复方制剂及其制备方法 | |
CN110420270A (zh) | 一种含有山茶油和鱼油的功能性组合物及其应用 | |
CN107997154A (zh) | 辅酶q10与芝麻油制备预防骨质疏松的保健食品配方及生产工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 510800 Guangdong city in Guangzhou Province, Xinhua Street, Huadu District, Tian Village Phoenix Road No. 10 building three Feng Shang business room 1306 Applicant after: Guangdong Medical University Applicant after: GUANGDONG RUNHE BIOTECHNOLOGY CO., LTD. Address before: 523808 Guangdong province Dongguan City Songshan Lake Science and Technology Park Metro output Road No. 1, Guangdong Medical College School of Medicine Applicant before: Guangdong Medical College Applicant before: GUANGDONG RUNHE BIOTECHNOLOGY CO., LTD. |
|
CB02 | Change of applicant information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wu Tie Inventor after: Yu Qiong Inventor after: Zou Liyi Inventor after: Cui Liao Inventor after: Lv Simin Inventor after: Ding Xisheng Inventor after: Qiu Yuansheng Inventor after: Tang Linzhi Inventor before: Wu Tie Inventor before: Yu Qiong Inventor before: Zou Liyi Inventor before: Cui Liao Inventor before: Lv Simin Inventor before: Ding Xisheng Inventor before: Qiu Yuansheng |
|
CB03 | Change of inventor or designer information | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Pan Junda Document name: Notification of Passing Examination on Formalities |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 523808 School of medicine of Guangdong Medical University, No. 1, Xincheng Avenue, Songshan Lake, Songshan Lake, Guangdong Province Applicant after: Guangdong Medical University Applicant after: GUANGDONG RUNHE BIOTECHNOLOGY CO., LTD. Address before: Guangzhou Xinhua Street, Huadu District, Tian Village Phoenix Road No. 10 building three Feng Shang business room 1306 Applicant before: Guangdong Medical University Applicant before: GUANGDONG RUNHE BIOTECHNOLOGY CO., LTD. |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141210 |
|
WD01 | Invention patent application deemed withdrawn after publication |